Lexaria Bioscience
LEXX
13 hedge funds and large institutions have $1.85M invested in Lexaria Bioscience in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
18% more funds holding
Funds holding: 11 → 13 (+2)
1.17% less ownership
Funds ownership: 8.86% → 7.69% (-1.2%)
35% less capital invested
Capital invested by funds: $2.83M → $1.85M (-$978K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$38.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$23.5K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.7K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$9.53K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$75K |
| 2 |
Morgan Stanley
New York
|
-$5.68K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ICM
1
Invenomic Capital Management
Boston,
Massachusetts
| $1.45M | +$38.1K | +6,694 | +2% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $198K | – | – | – |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $138K | +$18.7K | +3,288 | +11% |
|
|
4
UBS Group
Zurich,
Switzerland
| $17K | +$23.5K | +4,134 | New |
|
|
EWM
5
Edge Wealth Management
New York
| $13K | – | – | – |
|
|
MFM
6
MD Financial Management
Ottawa,
Ontario, Canada
| $11K | – | – | – |
|
|
7
Osaic Holdings
Scottsdale,
Arizona
| $8K | +$9.53K | +1,674 | +454% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $5K | +$6.85K | +1,204 | New |
|
9
Wells Fargo
San Francisco,
California
| $4K | +$5.69K | +1,000 | +4,000% |
|
|
APC
10
Aspire Private Capital
Cornelius,
North Carolina
| $2K | +$2.28K | +400 | New |
|
11
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
VF
12
Virtu Financial
New York
| – | -$75K | -11,941 | Closed |
|
|
13
Morgan Stanley
New York
| – | -$5.68K | -999 | -100% |
|
LEXX Hedge Fund Activity: Q4 2021 in Review
13 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q4 2021, worth a combined $1.85M — down 35% from $2.83M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LEXX positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Invenomic Capital Management, adding an estimated $38.1K. The largest seller was Virtu Financial, exiting entirely with an estimated $75K sold.
- 13 institutional investors held Lexaria Bioscience (LEXX) as of Q4 2021, up from 11 in Q3 2021.
- Funds reported $1.85M of Lexaria Bioscience stock for Q4 2021, down 35% quarter-over-quarter.
- 3 funds opened new Lexaria Bioscience positions in Q4 2021 and 1 closed out, a net change of +2 holders.
- The largest Lexaria Bioscience buyer in Q4 2021 was Invenomic Capital Management, an estimated $38.1K added.
- The largest Lexaria Bioscience seller in Q4 2021 was Virtu Financial, an estimated $75K sold.
Based on aggregated 13F filings for Q4 2021.